Talk:Alexion Pharmaceuticals

Donating Soliris in Germany
...in a rare expression of good will, and hoping for more media attention  46.138.95.18 (talk) 06:36, 6 November 2011 (UTC)

Alexion Pharmaceuticals page edits
Products: Soliris, Kanuma, Strensiq Revenue: US$ 2.604 bil (2015) Operating Income: US$ 536.671 mil (2015) Net income: US$ 144.385 mil (2015) Total assets: US$ 13.133230 bil (2015) Total equity: US$ 8.258616 bil (2015) Number of employees: 3,000 (2015) Website: www.alexion.com

It also employes about 3,000 people worldwide.

Acquisitions Synageva's main drug, Kanuma, received approval in the United Stations on December 8, 2015 and European approval on September 1, 2015.

The Synageva acquisiton was completed on June 22, 2015.

Kanuma Kanuma is also approved in the European Union and Japan.

KateDietz (talk) 20:07, 3 November 2016 (UTC)